▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #467 by analyst upside · 2026-11-12
KURA
Kura Oncology, Inc.
Healthcare · Market Cap $688M · P/E 0x
ANALYST PRICE TARGET
+312.0%
implied upside to consensus target
Current Price $7.73
Consensus Target $31.85
Bull Target $76.0
Bear Target $15.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
10
Hold
1
Sell
0
52-Week Low $6.75
52-Week High $13.9
YTD Return -25.2%
FUNDAMENTALS
Market Cap $688M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.37
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $79M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.75
52-Week High $13.9
Current Price $7.73
Bear Target $15.0
Bull Target $76.0
● Now $7.73 ● Target $31.85
TRADING DATA
Avg Volume 2.1M
YTD Return -25.2%
Analyst Count 13
Consensus Buy
Upside to Target +312.0%
Last Updated 2026-11-12

ANALYST SUMMARY

Kura Oncology, Inc. (KURA) is currently trading at $7.73 with a Wall Street consensus price target of $31.85, implying potential upside of 312.0% over the next 12 months. 13 analysts currently cover KURA, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $76.0, while the most cautious has a target of $15.0.

KURA operates in the Healthcare sector with a market capitalisation of $688M. The stock is down 25.2% year-to-date and is currently trading near the lower end of its 52-week range of $6.75 – $13.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ● Initiated
Overweight 2026-10-01 43% win rate (7 calls)
Citizens reit
Market Outperform → Market Outperform 2026-08-24 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-08-13 Building track record
Wedbush reit
Outperform → Outperform 2026-07-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-06-15 Building track record
Lake Street ● Initiated
Buy 2026-04-14 27% win rate (11 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-03-24 Building track record
UBS - Reiterated
Buy → Buy 2026-03-13 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →